Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S.

Mol Cell. 2003 Sep;12(3):541-52. Review.

2.

Ligand-induced ErbB receptor dimerization.

Lemmon MA.

Exp Cell Res. 2009 Feb 15;315(4):638-48. doi: 10.1016/j.yexcr.2008.10.024. Epub 2008 Oct 31. Review.

3.
4.

Binding specificities and affinities of egf domains for ErbB receptors.

Jones JT, Akita RW, Sliwkowski MX.

FEBS Lett. 1999 Mar 26;447(2-3):227-31.

5.

Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.

Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szöllosi J.

J Cell Sci. 2002 Nov 15;115(Pt 22):4251-62.

6.

Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions.

Adelsman MA, Huntley BK, Maihle NJ.

J Virol. 1996 Apr;70(4):2533-44. Erratum in: J Virol 1996 May;70(5):3330.

7.

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.

Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.

Oncogene. 1998 Mar 12;16(10):1249-58.

8.

Epidermal growth factor receptor (EGFR) signaling in cancer.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS.

Gene. 2006 Jan 17;366(1):2-16. Epub 2005 Dec 27. Review.

PMID:
16377102
9.

Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.

Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA.

EMBO J. 2000 Sep 1;19(17):4632-43.

10.
11.

Epidermal growth factor receptor cytoplasmic domain mutations trigger ligand-independent transformation.

Massoglia S, Gray A, Dull TJ, Munemitsu S, Kun HJ, Schlessinger J, Ullrich A.

Mol Cell Biol. 1990 Jun;10(6):3048-55.

12.

Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.

van der Woning SP, van Rotterdam W, Nabuurs SB, Venselaar H, Jacobs-Oomen S, Wingens M, Vriend G, Stortelers C, van Zoelen EJ.

J Biol Chem. 2006 Dec 29;281(52):40033-40. Epub 2006 Oct 10.

13.
14.

The ErbB/HER receptor protein-tyrosine kinases and cancer.

Roskoski R Jr.

Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11. Review.

PMID:
15158434
15.
16.

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA.

Mol Cell. 2003 Feb;11(2):507-17.

17.

Ligand discrimination in signaling through an ErbB4 receptor homodimer.

Sweeney C, Lai C, Riese DJ 2nd, Diamonti AJ, Cantley LC, Carraway KL 3rd.

J Biol Chem. 2000 Jun 30;275(26):19803-7.

18.

An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex.

McManus MJ, Boerner JL, Danielsen AJ, Wang Z, Matsumura F, Maihle NJ.

J Biol Chem. 2000 Nov 10;275(45):35328-34.

19.

Bivalence of EGF-like ligands drives the ErbB signaling network.

Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y.

EMBO J. 1997 Aug 15;16(16):4938-50.

20.

Studies on the betacellulin receptor in pancreatic AR42J cells.

Ishiyama N, Kanzaki M, Seno M, Yamada H, Kobayashi I, Kojima I.

Diabetologia. 1998 Jun;41(6):623-8.

PMID:
9662041
Items per page

Supplemental Content

Write to the Help Desk